Teladoc Health Files Proxy Materials

TL;DR

TDOC filed proxy docs, no fee. Shareholders get updates.

AI Summary

Teladoc Health, Inc. filed a Definitive Additional Materials proxy statement on May 5, 2025. This filing is related to the company's proxy materials and does not require a fee, as indicated by the filing of "No fee required". The filing is made under the Securities Exchange Act of 1934.

Why It Matters

This filing provides important information to shareholders regarding company matters, typically related to upcoming shareholder meetings and voting on corporate actions.

Risk Assessment

Risk Level: low — This is a routine proxy filing and does not contain information that inherently increases risk for investors.

Key Players & Entities

• Teladoc Health, Inc. (company) — Registrant
• 0001477449-25-000051 (filing_id) — Accession Number
• 20250505 (date) — Filing Date

FAQ

From the Filing

0001477449-25-000051.txt : 20250505 0001477449-25-000051.hdr.sgml : 20250505 20250505160523 ACCESSION NUMBER: 0001477449-25-000051 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20250505 DATE AS OF CHANGE: 20250505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Teladoc Health, Inc. CENTRAL INDEX KEY: 0001477449 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 043705970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-37477 FILM NUMBER: 25912875 BUSINESS ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 BUSINESS PHONE: 2036352002 MAIL ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 FORMER COMPANY: FORMER CONFORMED NAME: Teladoc, Inc. DATE OF NAME CHANGE: 20091123 DEFA14A 1 supplementalproxyletter.htm DEFA14A Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.         ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.14a-12 TELADOC HEALTH, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒ No fee required ☐ Fee paid previously with preliminary materials ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 Dear fellow stockholders: On April 8, 2025, Teladoc Health, Inc. (“Teladoc Health” or the “Company”) filed a definitive proxy statement in connection with our 2025 Annual Meeting of Stockholders, to be held on May 22, 2025 (the “Annual Meeting”). Say-on-Pay Proposal One of the proposals to be voted on by our stockholders at the Annual Meeting and described in our proxy statement is the advisory vote to approve executive compensation (“Proposal No. 2” or the “Say-on-Pay Proposal”). The Say-on-Pay Proposal vote is advisory and will not be binding upon us, our board of directors (our “Board”) or its compensation committee (our “Compensation Committee”), nor will it create or imply any change in the duties of us, our Board or our Compensation Committee. However, the outcome of the Say-on-Pay Proposal is of utmost importance to us, our Board and our Compensation Committee, in being responsive to and demonstrating our commitment to the interests of our stockholders. Our Compensation Committee believes the support received from stockholders last year demonstrates that our stockholders strongly approve of our philosophy, strategy, objectives and implementation of our executive compensation programs. Our executive compensation practices during 2024 were strongly influenced by the CEO transition that we experienced: we needed to recruit and properly incentivize our new CEO and also to retain certain members of our senior team to ensure continuity of leadership during and after the CEO search. Other than the compensation actions we took in connection with this CEO transition, our executive compensation philosophy and practices remained the same as in prior years, for which we historically received significant stockholder approval (including 95.9% approval in 2024). After considering our prior year’s say-on-pay proposal result and en